- Imipenem-Cilastatin sodium hydrate
-
- $0.00 / 5KG/Tin
-
2021-09-29
- CAS:92309-29-0
- Min. Order: 5KG
- Purity: Imipenem≥400μg/mg，Cilastatin(C16H26N2O5S) ≥400μg/mg;USP
- Supply Ability: 100KGS
|
| | Imipenem-Cilastatin sodium hydrate Basic information |
| Product Name: | Imipenem-Cilastatin sodium hydrate | | Synonyms: | Primaxin;Thienam;Tienam 500;IMipeneM and Cilastatin SodiuM with SodiuM Bicarbonate;7-[(2S)-2-amino-2-carboxy-ethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopro panecarbonyl]amino]hept-2-enoic acid: (5R)-3-[2-(aminomethylideneamino )ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene -2-carboxylic acid;Imipenem-Cilastatin sodium hydrate;Sodium (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate;1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-, mixt. with (2Z)-7-(((2R)-2-amino-2-carboxyethyl)thio)-2-((((1S)-2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic acid | | CAS: | 92309-29-0 | | MF: | C28H43N5O9S2 | | MW: | 657.8 | | EINECS: | 1592732-453-0 | | Product Categories: | | | Mol File: | 92309-29-0.mol |  |
| | Imipenem-Cilastatin sodium hydrate Chemical Properties |
| | Imipenem-Cilastatin sodium hydrate Usage And Synthesis |
| Clinical Use | Antibacterial agent | | Drug interactions | Potentially hazardous interactions with other drugs
Antiepileptics: reduced valproate concentration -
avoid.
Antivirals: convulsions reported with concomitant
administration of ganciclovir and valganciclovir.
Ciclosporin: variable reports of increase / no change
in ciclosporin levels, and of neurotoxicity. | | Metabolism | When administered alone, imipenem is metabolised in
the kidneys by dehydropeptidase-I, an enzyme in the
brush border of the renal tubules, to inactive, nephrotoxic
metabolites, with only about 5 to 40 or 45% of a dose
excreted in the urine as unchanged active drug.
Cilastin inhibits the metabolism of imipenem. When
given with cilastatin about 70% of an intravenous dose of
imipenem is recovered unchanged in the urine within 10
hours. Cilastatin is also excreted mainly in the urine, the
majority as unchanged drug and about 12% as N-acetyl
cilastatin. Less than 1% of imipenem is excreted via the
bile in the faeces. |
| | Imipenem-Cilastatin sodium hydrate Preparation Products And Raw materials |
|